

NCTN Sarcoma Trials Portfolio (Open as of 4/15/2024)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

Newly Diagnosed Disease

Rhabdomyosarcoma (RMS)

ARST2031 (High risk)

Liposarcoma (Mets/Locally advanced)

A092107

Osteosarcoma (Pulmonary Mets)

AOST2031

Osteosarcoma (Metastatic)

AOST2032

Retroperitoneal Sarcoma

EA7211 (STRASS 2) (High risk)

Recurrent Disease

Osteosarcoma (Pulmonary Mets)

AOST2031

Liposarcoma (Locally advanced)

A092107

Legend by Disease Types

Green = Rhabdomyo-
sarcoma (RMS)

Blue = Liposarcoma

Yellow =
Osteosarcoma

Yellow = Retroperitoneal
Sarcoma

Cross-disease trials

EAY191 (ComboMATCH)

Sub-study:
EAY191-A3
(RAS-mutant)

Sub-study:
EAY191-E4
(Prior Taxane-
treated)

Sub-study:
EAY191-E5
(KRAS G12C
mutation)

Sub-study:
EAY191-N5
(HER2
amplified)

Sub-study:
EAY191-S3
(Activating AKT
mutation)

NCTN Sarcoma Trials (Open as of 4/15/2024)

Protocol Number	Phase	Protocol Title
A092107	II	A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
ARST2031	III	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
EA7211	III	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-A3	II	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-E4	II	Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
EAY191-E5	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191-N5	II	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAY191-S3	II	Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>